# Efficacy and Safety Study of Proposed Biosimilar Product Reveliza vs Actilise in Patients With ST-segment Elevation Myocardial Infarction

> **NCT07146360** · PHASE3 · COMPLETED · sponsor: **AO GENERIUM** · enrollment: 180 (actual)

## Conditions studied

- Myocardial Infarction (MI)

## Interventions

- **BIOLOGICAL:** Revelise (GENERIUM, Russia)
- **BIOLOGICAL:** Actilyse® (Boehringer Ingelheim Pharma GmbH and Co.KG, Germany)

## Key facts

- **NCT ID:** NCT07146360
- **Lead sponsor:** AO GENERIUM
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-05-25
- **Primary completion:** 2017-11-21
- **Final completion:** 2017-12-11
- **Target enrollment:** 180 (ACTUAL)
- **Last updated:** 2025-08-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07146360

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07146360, "Efficacy and Safety Study of Proposed Biosimilar Product Reveliza vs Actilise in Patients With ST-segment Elevation Myocardial Infarction". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT07146360. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*